In This Article:
What Happened?
Shares of medical device company CooperCompanies (NASDAQ:COO) fell 15% in the afternoon session after the company reported underwhelming first-quarter 2025 results (fiscal Q2), with sales exceeding expectations by a whisker while organic sales growth guidance for the full year was lowered. Management called out "softening in two of its growth markets, contact lenses and fertility."
On a brighter note, COO raised its full-year revenue and EPS guidance, off the back of the modest beat. In addition, its organic revenue and EPS outperformed Wall Street's estimates during the quarter. Overall, this print had some key positives. Investors were likely hoping for more.
The shares closed the day at $68.25, down 14.7% from previous close.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy CooperCompanies? Access our full analysis report here, it’s free.
What The Market Is Telling Us
CooperCompanies’s shares are not very volatile and have only had 6 moves greater than 5% over the last year. Moves this big are rare for CooperCompanies and indicate this news significantly impacted the market’s perception of the business.
CooperCompanies is down 24.7% since the beginning of the year, and at $68.28 per share, it is trading 38.6% below its 52-week high of $111.23 from September 2024. Investors who bought $1,000 worth of CooperCompanies’s shares 5 years ago would now be looking at an investment worth $866.55.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.